Roche is considering its options in the US
Keystone / Dominik Pluess
Generated with artificial intelligence.
Swiss pharmaceutical firm Roche could reconsider investing billions of dollars in the United States after President Donald Trump's pledge to lower medication costs.
Roche and Novartis have both recently announced huge US investments, partly in the hope of gaining goodwill from Trump’s administration. But the US is now targeting substantial price reductions on medications.
“If the proposed executive order goes into effect, the significant investments in the US we previously announced would be put to the test,” said a Roche spokesperson, confirming a report in the Neue Zürcher Zeitung.
A little over a month ago, Novartis announced it would invest $23 billion in additional factories and research laboratories in the US over the next five years. Roche plans to spend $50 billion on capacity expansion over the same period.
Trump’s executive order has instructed the US Department of Health and Human Services to begin negotiations with pharmaceutical companies within the next 180 days.
The department is expected to compile a list of benchmark prices within the next 30 days. If the manufacturers don’t lower the prices themselves, the Trump administration will attempt to do so through legislation.
More
Trump’s promise to lower drug prices rattles Swiss pharma stocks
This content was published on
US President Trump wants to make medicines cheaper in the US, which could mean huge losses for drugmakers, including those in Switzerland.
We select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate them into English. A journalist then reviews the translation for clarity and accuracy before publication. Providing you with automatically translated news gives us the time to write more in-depth articles. The news stories we select have been written and carefully fact-checked by an external editorial team from news agencies such as Bloomberg or Keystone.
Did you find this explanation helpful? Please fill out the short survey below to help us understand your needs.
External Content
More
Unstable Swiss glacier still cause for concern
This content was published on
An unstable glacier above the Swiss village of Blatten has stopped breaking up, but there is still no question of lifting a landslide alert.
Swiss education chief wants fewer mobile phones in schools
This content was published on
The new head of the Swiss cantonal education authority would like to ban mobile phones in schools, apart from use in lessons.
Swiss regulator criticises banks for being lax with mortgages
This content was published on
Switzerland's financial watchdog has condemned a tendency for banks to apply less stringent internal guidelines for granting mortgage loans.
Uber drivers subject to the law on services in Geneva
This content was published on
The Federal Court has ruled against a Geneva-based company, a partner of Uber, which challenged its liability under the law on the hiring of services.
Swiss nuclear power plants are not at risk from flooding
This content was published on
According to an inspection by the Swiss Federal Nuclear Safety Inspectorate, the safety-relevant buildings of the Swiss nuclear power plants are not at risk.
SWI swissinfo.ch – the international service of the Swiss Broadcasting Corporation (SBC).
Since 1999, swissinfo.ch has fulfilled the federal government’s mandate to distribute information about Switzerland internationally, supplementing the online offerings of the radio and television stations of the SBC. Today, the international service is directed above all at an international audience interested in Switzerland, as well as at Swiss citizens living abroad.
